Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy

Haematologica

Volumn 100, Issue 12, 2015, Pages e515-e518

  Visentin, Andrea ^a,b   Compagno, Nicolò ^a,b   Cinetto, Francesco ^a,b   Imbergamo, Silvia ^a   Zambello, Renato ^a,b   Piazza, Francesco ^a,b   Semenzato, Gianpietro ^a,b   Trentin, Livio ^a,b   Agostini, Carlo ^a,b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

CLL; Hypogammaglobulinemia; Immunoglobulin replacement therapy; Infections; Secondary hypogammaglobulinemia

Indexed keywords

IMMUNOGLOBULIN;

ADULT; AGED; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; LETTER; MAJOR CLINICAL STUDY; MALE; MONOCLONAL B CELL LYMPHOCYTOSIS; RETROSPECTIVE STUDY; SUBSTITUTION THERAPY; INFECTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICROBIOLOGY; MIDDLE AGED; MORTALITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFECTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED;

EID: 84949035173     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.126763     Document Type: Letter

References (15)

1. Dhalla F, Lucas M, Schuh A, et al. Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin? J Clin Immunol. 2014;34 (3):277-282.
2. Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573-581.
3. Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27(1):136-141.
4. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2008(4):CD006501.
5. Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626.
6. Compagno N, Cinetto F, Semenzato G, Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximabrelated secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica. 2014;99(6):1101-1106.
7. Francis S, Karanth M, Pratt G, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107(5):1023-1033.
8. Hensel M, Kornacker M, Yammeni S, Egerer G, Ho AD. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol. 2003;122(4):600-606.
9. Parikh SA, Leis JF, Chaffee KG, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer. 2015;21(17):2883-2891.
10. Oscier D, Dearden C, Eren E, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159(5):541-564.
11. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(2 Suppl 1):S9-56.
12. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525-553.
13. Freeman Ja, Crassini KR, Best OG, et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(1):99-104.
14. Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90(5):446-460.
15. Strati P, Keating MJ, Wierda WG, et al. Lenalidomide induces longlasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013;122(5):734-737.